7 results about "Mental retardations" patented technology

The application discloses a kind of composite nutrient composition and its application in intervention autism and mental retardation, the composite nutrient composition is composed of composite vitamin, mineral, enterobacterium, apple fruit powder and the substance for improving taste;Wherein, the procyanidin B1 content in the apple fruit powder is more than 30mg / kg, the composite nutrient composition of the application can effectively improve the repetitive stereotyped behavior of autistic children, the degree of anxiety, the degree of cognition, and social skills, and effectively improve the intestinal flora imbalance phenomenon of autistic children.It can also effectively improve the cognitive ability of children with mental retardation.

New gelatinase inhibitors, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and / or prophylaxis of conditions wherein inhibition of gelatinases is useful such as epilepsy, schizophrenia, Alzheimer disease, autism (in particular associated to fragile X syndrome), mental retardation, mood disorders such as bipolar disorders, depression, vascular diseases such as ischemic stroke and atherosclerosis, inflammatory diseases such as multiple sclerosis and rheumatoid arthritis, drug addiction, neuropathic pain, lung diseases such as asthma and chronic obstructive pulmonary disease, cancer and sepsis.

The application provides application of polycyclic polyisoprenyl acyl phloroglucinol compounds (PPAP) of two different skeleton types in preparation of medicines for relieving / treating neurodegenerative diseases. The application belongs to the technical field of medicines. The hyphenrone A provided by the application is a 1,9-cracked polycyclic polyisoprenyl acyl phloroglucinol compound, and the hyphenrone L is a polycyclic polyisoprenyl acyl phloroglucinol compound with a complex ring system formed by intramolecular [4+2] cyclization of a monocyclic polyisoprenyl acyl phloroglucinol compound. The compound hyphenrone A and the compound hyphenrone L both have the activity of enhancing the voltage-gated T-type calcium channel current, and can be used for preparing medicines for treating neurodegenerative diseases, and in particular, can be used for preparing medicines for relieving and / or treating diseases such as spinocerebellar ataxia, Alzheimer's disease and mental retardation syndrome, and have the clinical application value.

The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, epilepsy, autism spectrum disorders, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

The invention relates to a compound, in particular to a medicine for treating cranial nerve dysfunction diseases, namely alpha-asarone and an isomer beta-asarone, the molecular formula is C12H16O3, the molecular weight is 208.26, the Chinese name is 2, 4, 5-trimethoxy-1-propenyl benzene, and a preparation prepared from the alpha-asarone and the isomer beta-asarone can be used for treating cranial nerve dysfunction diseases. The pharmaceutical composition is used for treating various memory, cognition, sensory integration and thinking function partial or all deficiency diseases caused by cranial nerve dysfunction, including Alzheimer's disease, dementia, encephalitis sequelae, cerebral palsy, children intellectual development disorder, autism, hyperactivity and the like.

The invention discloses a composition for treating dysgnosia and application thereof. According to the invention, the AAV virus carrying the hCAPZA2 gene is introduced into a CAPZA2 heterozygous knockout or mutated mouse model, and the effectiveness of the AAV virus in the aspects of improving the CAPZA2 expression level, recovering the synaptic function and improving the neural behavior is verified. The invention not only provides a new hope for treating the mental disorder related to the CAPZA2 gene, but also opens up a new direction for the application of gene therapy in neurodevelopment diseases.